PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. ACN

Go back to PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
(NASDAQ: PEPG) Delayed: 2.84 -0.01 (0.35%)
Previous Close $2.85    52 Week High $ 
Open $2.88    52 Week Low $ 
Day High $2.92    P/E N/A 
Day Low $2.80    EPS $ 
Volume 652,374